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cost approach, the estimates were similar when patient demographic and clinical
characteristics were controlled for in the incremental cost approach.
PMH30
THE SOCIETAL COST OF DEPRESSION: EVIDENCE FROM 10,000 SWEDISH
PATIENTS IN PSYCHIATRIC CARE
Ekman M1, Granström O2, Omerov S3, Jacob J2, Landén M4
1i3 Innovus, Stockholm, Sweden, 2AstraZeneca Nordic MC, Södertälje, Sweden, 3Northern
Stockholm Psychiatry, Stockholm, Sweden, 4Gothenburg University, Göteborg, Sweden
OBJECTIVES: Depression is a major health problem. Previous studies on the cost of
depression have mainly taken a primary care perspective. Such studies do not
include all patients with depression, and should be completed by cost estimates
from psychiatric care. The objectives of this study were to estimate the annual
societal cost of depression per patient in psychiatric care in Sweden, and to relate
costs to disease severity, depressive episodes, hospitalization, and patient
functioning. METHODS: Retrospective resource use data in inpatient and outpa-
tient care for 2006-2008, as well as ICD-10 diagnoses and Global Assessment of
Functioning (GAF), were obtained fromNorthern Stockholm psychiatric clinic with
a catchment area including 47% of the adult inhabitants in Stockholm city. This
data setwas combinedwith national register data on prescription pharmaceuticals
and sick leave to estimate the societal cost of depression. RESULTS: The study
included 10,593 patients (63%women). The average annual societal cost per patient
was aroundUSD 21,000 in 2006-2008. The largest cost itemwas indirect costs due to
productivity losses (89%), and the second largest was outpatient care (6%). Patients
with mild, moderate or severe depression had an average cost of approximately
USD 18,000, USD 21,000, andUSD 29,000, respectively. Total costswere significantly
higher during depressive episodes, for patients with co-morbid psychosis or anxi-
ety, for hospitalized patients, and for patientswith lowGAF scores.CONCLUSIONS:
The largest share of societal costs for patientswith depression in psychiatric care is
indirect. The total costs were higher than previously reported from a primary care
setting, and strongly related to hospitalization, episodes of active depression, and
global functioning. This suggests that effective treatment and rehabilitation that
avoid depressive episodes and hospitalization may not only improve patient
health, but also reduce the societal cost of depression.
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OBJECTIVES: Estimate the cost of a psychiatric relapse in the Brazilian private
healthcare system. METHODS: Using a claims database, 842 patients were classi-
fied according to one of the following diagnoses: organic delusional disorder
(schizophrenia-like), schizophrenia, schizotypal disorder, persistent delusional
disorder or schizoaffective disorder. During 26 months, from August/2009 to Sep-
tember/2011, all patients that first used the private healthcare system were ana-
lyzed and followed. All costs associated with the treatment of schizophrenia were
considered across seven major categories: hospitalization, medications, proce-
dures, materials, exams, alimentation and hygiene care. RESULTS: Out of the 842
patients that used the private health care system in a period of 26 months, 388
returned to the hospital (“return patients”, 46%) and accounted for 85% (R$
8,800,518.79) of the costs during the period of the analysis. The majority of the
“return patients”, 57% (n221), were re-hospitalized between 2 and 4 times, and 9%
(n35) returned 20 times or more during the period studied. “Return patients”
presented an average total cost of R$ 22,681.75/patient in 26 months, a cost per
patientmore than 6 times higherwhen comparedwith those that did not return (R$
3,511.72/patient/26 months). Most costs were accountable to hospitalization (75%),
followed by medication (14%). The most frequently used medications by the 842
patients, in units, in decreasing order were: levomepromazine, haloperidol and
clonazepam. CONCLUSIONS: Although patients with hospitalizations represented
46% of the sample, they accounted for 85% of the costs occurred in the 2 year
period. As a result, avoiding hospitalization in psychiatric relapse could be an
effective cost-saving investment. Furthermore, the claims database does not con-
sider all outpatient costs incurred by the sample, so these results might be under-
estimated.
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OBJECTIVES:Compare the health care utilization achieved by patientswith schizo-
phrenia and bipolar disorder using atypical and typical antipsychotics.METHODS:
Episodes of antipsychotic therapy were identified using data from California Med-
icaid program from 1994 to 2003. The first observed episode for each patient was
then excluded leaving four types of episodes: restarting therapy using the same
drug as the preceding episodes after a discontinuation; switching therapy using a
different drug after a break in treatment; switching therapy without a break in
treatment, and augmentation. A propensity score model of atypical antipsychotic
use was estimated using drug therapy episodes between Oct 1997, the first month
that the atypical antipsychotics were available without restrictions, and Dec 2002.
A total of 296,284 episodes of atypical antipsychotic therapy were matched with
typical antipsychotic drug therapy identified using all restart, switching and aug-
mentation episodes identified in the period 1994-2003. The impact of atypical an-
tipsychotic use on health care utilization patterns over a one-year post-treatment
period were analyzed using OLS regressions. RESULTS: Atypical antipsychotic use
increased total one year post-treatment cost by $583 dollars (p0.0001) for restart
episodes, $1620 dollars for delayed switch episodes (p0.0001) and$1318 dollars
(p0.0001) for switch episodes. The use of atypical antipsychotics was not associ-
ated with any statistically significant change in total cost for augmentation epi-
sodes. For all four types of episodes, using atypical antipsychotics was associated
with significantly higher one year post-treatment drug costs ($375 to $1413) which
were partially offset by significant reductions inmedical costs for switching, restart
and augmentation episodes. Using atypical antipsychotics reduced acute hospital
admission but hadmixed effects on psychiatric hospital and nursing home admis-
sion across episode types. CONCLUSIONS: There is some evidence that the in-
creased drug costs associated with atypical antipsychotics use are partially offset
by decreased costs of other medical services.
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OBJECTIVES: The aim of the present study was to conduct an economic evaluation
comparing Agomelatine with its most common alternatives in daily clinical prac-
tice for treating patients with Major depressive disorder (MDD) in Greece.
METHODS: An existing Markov model evaluating the 2-year cost-effectiveness of
Agomelatinewas adapted to the Greek setting. Themodel consists of six states and
the cycle length was set to one month. The analysis was conducted by the Greek
societal perspective. Input data (i.e. transition probabilities, costs assigned to each
health state, utility values and probabilities for adverse events) were obtained from
published literature, government sources, and experts’ opinion. Head-to-head
clinical trials of Agomelatine versus active comparators (if available) were used,
and indirect comparisons were conducted in the absence of directly comparative
trials. Both direct and indirect costswere considered in themodel. The resultswere
expressed as incremental cost-effectiveness ratios (ICERs) per quality-adjusted-
life-year (QALY) gained. RESULTS: The Markov model revealed that the average
total cost related to 2-year treatment of MDDwith Agomelatine is lower compared
to Venlafaxine (€43), Sertraline (€257), Escitalopram (€57) and Fluoxetine (€174) and
higher compared to Mirtazapine (€304) and Citalopram (€217). Moreover, the aver-
age QALYs for Agomelatine-treated patients was found to be higher against all
comparators. In particular, the increment in QALYs varies between 0.015 and 0.088
against Escitalopram and Mirtazapine, respectively. Therefore, Agomelatine is
dominant against all comparators with the exception of Mirtazapine and Citalo-
pram where it is cost-effective (ICER: €26,662/QALY and €11,055/QALY gained, re-
spectively). The probabilistic sensitivity analysis revealed that Agomealtine is cost-
effective against all comparators with a probability between 48.9% and 97% at a
willingness-to-pay threshold of €50,000/QALY gained. CONCLUSIONS: Using con-
servative assumptions, the present economic evaluation indicates that Agomela-
tine may be a more efficient therapy compared to its alternatives for the manage-
ment of patients in Greece.
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OBJECTIVES: To evaluate long-term cost-effectiveness (including hospitalizations
and cardiometabolic consequences) of atypical antipsychotics (AAPs) among
adults with schizophrenia. METHODS: A 5-year Markov cohort cost-effectiveness
model, from a US payer perspective, was developed to compare lurasidone, gener-
ic-olanzapine, aripiprazole, quetiapine, and ziprasidone. Health states included in
the model were: patients on initial AAP; patients switched to a second AAP; and
patients on clozapine after failing a second AAP. Incremental cost-effectiveness
ratios (ICERs) assessed incremental cost/hospitalization avoided. Effectiveness in-
puts included discontinuations, hospitalizations, weight change, and cholesterol
change from comparative clinical trials for lurasidone and for aripiprazole, and
CATIE for other comparators. AAP-specific relative risk of diabetes obtained from a
retrospective analysiswas used to predict cardiometabolic events per the Framing-
ham BMI risk equation. Mental health costs (relapsing versus non-relapsing pa-
tients) and medical costs associated with cardiometabolic consequences (cardio-
vascular events and diabetesmanagement) were obtained frompublished sources.
AAP costs were estimated from Redbook prices at dose(s) reported in the clinical
data sources used in the model (e.g., weighted average dose of lurasidone and
average dose for all other comparators). Costs and outcomes were discounted at
3%, and model robustness was tested using one-way and probabilistic sensitivity
analyses. RESULTS: In a 5-year period, lurasidone dominated ziprasidone, quetia-
pine, and aripiprazole in terms of incremental cost/hospitalization avoided. Com-
pared with generic-olanzapine ($106,407 and 0.424 hospitalizations), lurasidone
patients had an ICER of $16,522/hospitalization avoided ($107,219 and 0.374 hospi-
talizations). Lurasidone had an 89.5% probability of being cost-effective compared
with generic-olanzapine at a willingness-to-pay of $50,000/hospitalization
avoided. One-way sensitivity analysis showed the model is sensitive to hospital-
ization rates and AAP costs. CONCLUSIONS:Model results show that among adults
with schizophrenia, lurasidone is cheaper and more effective versus ziprasidone,
quetiapine, and aripiprazole, and would be cost-effective compared with generic-
olanzapine, due to differences in hospitalization rates and cardiometabolic profile.
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